Targeting Lewis Y (Ley) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: A pilot trial testing two dose levels

Journal of Thoracic Oncology

Volumn 2, Issue 10, 2007, Pages 947-952

  Krug, Lee M ^a,d   Milton, Daniel T ^a   Jungbluth, Achim A ^b   Chen, Lin Chi ^a   Quaia, Emilio ^a   Pandit Taskar, Neeta ^a   Nagel, Andrew ^a   Jones, Jessica ^a   Kris, Mark G ^a   Finn, Ronald ^a   Smith Jones, Peter ^a   Scott, Andrew M ^c   Old, Lloyd ^b   Divgi, Chaitanya ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hu3S193; Lewis Y; Monoclonal antibody; Small cell lung cancer

Indexed keywords

FLUORODEOXYGLUCOSE; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU 3S193; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SCREENING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SCINTILLATION CAMERA; SCREENING TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LEWIS BLOOD-GROUP SYSTEM; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; RADIOIMMUNOTHERAPY; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 34848863393     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181560dcc     Document Type: Article

References (23)

1. Souhami RL, Beverly PCL, Bobrow LG, Ledermann JA. Antigens of lung cancer: results of the Second International Workshop on Lung Cancer Antigens. J Natl Cancer Inst 1991;83:809-812.
2. Stahel RA, Lacroix H, Sculier JP, et al. Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. Ann Oncol 1992;3:319-320.
3. Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992;327:14-18.
4. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 1997;73:50-56.
5. Kitamura K, Stockert E, Garin-Chesa P, et al. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci U S A 1994;91:12957-12961.
6. Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60:3254-3261.
7. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 2000;6:3621-3628.
8. Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med 2006;47:716-725.
9. Boghaert ER, Sridharan L, Armellino DC, et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewis y-positive human carcinoma cells and xenografts. Clin Cancer Res 2004;10:4538-4549.
10. Scott AM, Tebbutt N, Lee FT, et al. A phase 1 biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3S193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res. 2007;13:3286-3292.
11. Kobayashi H, Wu C, Yoo TM, et al. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med 1998;39:829-836.
12. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237-5243.
13. Lindmo T, Bunn PA Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 1986;121:678-691.
14. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001;61:6851-6859.
15. Steplewski Z, Lubeck MD, Scholz D, Loibner H, McDonald Smith J, Koprowski H. Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide. In Vivo 1991;5:79-83.
16. Theodoulou M, Gilewski T, Welt S, et al. Anti-Lewis Y (LeY) monoclonal antibody (mAb) BR55-2 (IgG2a) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1994;13:A974.
17. Pai LH, WR, Setser A, et al. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2:350-353.
18. Pai-Scherf LH, Carrasquillo JA, Paik C, et al. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3. Clin Cancer Res 2000;6:1720-1730.
19. Oruzio DV, Aulmann C, Eller N, et al. Results from a phase I clinical trial with IGN311, a fully humanized IgG1 antibody against Lewis Y in patients with solid tumors expressing Lewis Y antigen. Proc Am Sci Clin Oncol 2004:A2624.
20. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261:212-215.
21. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000;18:2282-2292.
22. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999;17:478-484.
23. Ross HJ, Hart LL, Swanson PM, et al. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 2006;54:69-77.